2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-126034
    3,4-Dichloroisocoumarin 51050-59-0
    3,4-Dichloroisocoumarin is a potent serine-protease and SrLip inhibitor (Ki for SrLip: 26.6 μM). 3,4-Dichloroisocoumarin is opened by serine proteases and then undergoes acylation with the enzyme, thereby inhibiting protease activity. 3,4-Dichloroisocoumarin can induce DNA fragmentation and Apoptosis. 3,4-Dichloroisocoumarin can be used in the research of multiple fields such as tumors, cardiovascular disease and enzyme catalytic mechanisms.
    3,4-Dichloroisocoumarin
  • HY-N0390S
    L-Glutamine-15N 80143-57-3 ≥98.0%
    L-Glutamine-15N is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells.
    L-Glutamine-15N
  • HY-N11848
    D-Glucosamine 6-phosphate 3616-42-0 ≥99.0%
    D-Glucosamine 6-phosphate is an endogenous metabolite that can be synthesized by glutamine fructose-6-phosphate amidotransferase (GFAT). D-Glucosamine 6-phosphate can be used for the research of diabetes mellitus.
    D-Glucosamine 6-phosphate
  • HY-N7389A
    GDP-D-mannose disodium 103301-73-1 ≥98.0%
    GDP-D-mannose disodium contains GDP-α-D-mannose (HY-N7389B) and GDP-β-D-mannose. GDP-α-D-mannose is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM).
    GDP-D-mannose disodium
  • HY-132586A
    Viltolarsen sodium
    Viltolarsen (NS-065/NCNP-01) sodium is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen sodium binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen sodium has the potential for Duchenne muscular dystrophy (DMD) research.
    Viltolarsen sodium
  • HY-N0390S8
    L-Glutamine-15N2 204451-48-9 ≥98.0%
    L-Glutamine-15N2 is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells.
    L-Glutamine-15N2
  • HY-W014930
    DL-5-Hydroxylysine hydrochloride 13204-98-3 ≥98.0%
    DL-5-Hydroxylysine hydrochloride is an endogenous metabolite.
    DL-5-Hydroxylysine hydrochloride
  • HY-W016715
    L-Cysteine hydrochloride hydrate 7048-04-6 ≥98.0%
    L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and insulin and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes.
    L-Cysteine hydrochloride hydrate
  • HY-W053787
    1-Methylhistamine dihydrochloride 6481-48-7 ≥98.0%
    1-Methylhistamine dihydrochloride is a histamine metabolite.
    1-Methylhistamine dihydrochloride
  • HY-14342
    MK-5046 1022152-70-0 99.67%
    MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity.
    MK-5046
  • HY-108742
    Abaloparatide 247062-33-5 99.94%
    Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis.
    Abaloparatide
  • HY-B0166R
    L-Ascorbic acid (Standard) 50-81-7 99.97%
    L-Ascorbic acid (Standard) is the analytical standard of L-Ascorbic acid. This product is intended for research and analytical applications. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.
    L-Ascorbic acid (Standard)
  • HY-13646
    Encequidar 849675-66-7 ≥98.0%
    Encequidar (HM30181; HM30181A) is a potent and selective inhibitor of P-glycoprotein.
    Encequidar
  • HY-B0838
    Imidacloprid 138261-41-3 98.45%
    Imidacloprid is an effective and widely used neonicotinoid pesticide to control pests of cereals, vegetables, tea and cotton.
    Imidacloprid
  • HY-112233
    O-304 1261289-04-6 99.53%
    O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications .
    O-304
  • HY-145157
    Ferric nitrilotriacetate 16448-54-7 ≥98.0%
    Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis.
    Ferric nitrilotriacetate
  • HY-32339
    Maxacalcitol 103909-75-7 99.71%
    Maxacalcitol (22-Oxacalcitriol), a vitamin D3 (HY-15398) analog, is an orally active VDR agonist. Maxacalcitol has a limited calcemic effect. Maxacalcitol has the potential for psoriasis and hyperparathyroidism research.
    Maxacalcitol
  • HY-B0442
    Vardenafil 224785-90-4 99.81%
    Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes[1]-[6].
    Vardenafil
  • HY-117958
    HJC0197 1383539-73-8 99.58%
    HJC0197 is a potent Epac1 (exchange protein directly activated by cAMP 1) and Epac2 (IC50=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 inhibits Epac1-mediated Rap1-GDP exchange activity at 25 μM in the presence of equal concentration of cAMP.
    HJC0197
  • HY-P99365
    Ravulizumab 1803171-55-2
    Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
    Ravulizumab
Cat. No. Product Name / Synonyms Application Reactivity